GKOS - Glaukos Corporation

NYSE - NYSE Delayed Price. Currency in USD
40.45
-0.16 (-0.39%)
At close: 4:02PM EDT

40.45 0.00 (0.00%)
After hours: 4:44PM EDT

Stock chart is not supported by your current browser
Previous Close40.61
Open40.57
Bid0.00 x 1000
Ask0.00 x 800
Day's Range40.22 - 41.42
52 Week Range23.08 - 46.50
Volume309,522
Avg. Volume402,882
Market Cap1.426B
Beta1.03
PE Ratio (TTM)N/A
EPS (TTM)-0.17
Earnings DateMay 4, 2017 - May 5, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.83
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents3 hours ago

    Edited Transcript of GKOS earnings conference call or presentation 2-Aug-18 8:30pm GMT

    Q2 2018 Glaukos Corp Earnings Call

  • GlobeNewswire15 hours ago

    Investor Expectations to Drive Momentum within American Vanguard, Glaukos, United Natural Foods, Walker & Dunlop, Unisys, and Comfort Systems — Discovering Underlying Factors of Influence

    NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of American ...

  • Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
    Zacks12 days ago

    Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates

    Glaukos (GKOS) delivered earnings and revenue surprises of -15.38% and 5.85%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press12 days ago

    Glaukos: 2Q Earnings Snapshot

    The San Clemente, California-based company said it had a loss of 15 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Business Wire12 days ago

    Glaukos Announces Pharmaceutical Development Agreement with D. Western Therapeutics Institute, Inc.

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced it has entered into a research and development collaboration agreement with D. Western Therapeutics Institute (DWTI), a Japanese biotechnology company focused on the discovery and development of innovative new drugs to serve patients worldwide.

  • Business Wire12 days ago

    Glaukos Corporation Announces Second Quarter 2018 Financial Results

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the second quarter ended June 30, 2018.

  • ACCESSWIRE12 days ago

    Glaukos Corp to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Glaukos Corp (NYSE: GKOS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern Time. To listen ...

  • ACCESSWIRE15 days ago

    Free Pre-Market Technical Recap on DENTSPLY SIRONA and Three Additional Medical Supplies Stocks

    On Monday, July 30, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Seven out of nine sectors ended Monday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: DENTSPLY SIRONA Inc. (NASDAQ: XRAY), Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS), and Valeritas Holdings Inc. (NASDAQ: VLRX).

  • Business Wire27 days ago

    Glaukos Corporation to Release Second Quarter 2018 Financial Results after Market Close on August 2

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, plans to release second quarter 2018 financial results after the market close on Thursday, August 2, 2018. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m. EDT) on August 2, 2018.

  • See what the IHS Markit Score report has to say about Glaukos Corp.
    Markitlast month

    See what the IHS Markit Score report has to say about Glaukos Corp.

    Short interest is high for GKOS with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting GKOS. The net inflows of $3.59 billion over the last one-month into ETFs that hold GKOS are among the highest of the last year, but the rate of growth is slowing.

  • ACCESSWIRE2 months ago

    Free Technical Research on Valeritas Holdings and Three More Medical Supplies Equities

    On Thursday, June 28, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Seven out of nine sectors ended Thursday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Medical Instruments & Supplies equities this morning: Valeritas Holdings Inc. (NASDAQ: VLRX), Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), and Glaukos Corp. (NYSE: GKOS).

  • Business Wire2 months ago

    Glaukos Announces FDA Approval for the iStent inject® Trabecular Micro-Bypass System

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced it has received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) for the iStent inject® Trabecular Micro-Bypass System indicated for the reduction of intraocular pressure (IOP) in adult mild-to-moderate primary open-angle glaucoma (POAG) patients undergoing concomitant cataract surgery.

  • Business Wire2 months ago

    Glaukos Announces Participation in William Blair Growth Stock Conference

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the William Blair Growth Stock Conference on Tuesday, June 12, 2018, at 2:50 p.m. CDT in Chicago, IL. Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness.

  • ACCESSWIRE3 months ago

    Free Daily Technical Summary Reports on Endologix and Three Other Medical Supplies Stocks

    Ahead of today's trading session, WallStEquities.com scans Daxor Corp. (NYSE AMER: DXR), Endologix Inc. (NASDAQ: ELGX), Glaukos Corp. (NYSE: GKOS), and Halyard Health Inc. (NYSE: HYH). Companies in the Medical Instruments and Supplies space manufacture and sell medical devices, instrument systems, and reagents and consumables.

  • Glaukos Gets RS Rating Upgrade
    Investor's Business Daily3 months ago

    Glaukos Gets RS Rating Upgrade

    A Relative Strength Rating upgrade for Glaukos shows improving technical performance. Will it continue?

  • Is There Now An Opportunity In Glaukos Corporation (NYSE:GKOS)?
    Simply Wall St.3 months ago

    Is There Now An Opportunity In Glaukos Corporation (NYSE:GKOS)?

    Glaukos Corporation (NYSE:GKOS), a medical equipment company based in United States, received a lot of attention from a substantial price increase on the NYSE over the last few months. WithRead More...

  • Thomson Reuters StreetEvents3 months ago

    Edited Transcript of GKOS earnings conference call or presentation 9-May-18 8:30pm GMT

    Q1 2018 Glaukos Corp Earnings Call

  • Associated Press3 months ago

    Glaukos: 1Q Earnings Snapshot

    On a per-share basis, the San Clemente, California-based company said it had a loss of 8 cents. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...

  • Business Wire3 months ago

    Glaukos Corporation Announces First Quarter 2018 Financial Results

    Glaukos Corporation , an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced financial results for the first quarter ended March 31, 2018.

  • Business Wire3 months ago

    Glaukos Announces Participation in Bank of America Merrill Lynch 2018 Health Care Conference

    Glaukos Corporation (GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, today announced that its management is scheduled to participate in the Bank of America Merrill Lynch 2018 Health Care Conference on Wednesday, May 16, 2018, at 3:00 p.m. PDT in Las Vegas, Nevada. Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to transform the treatment of glaucoma, one of the world’s leading causes of blindness.

  • Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
    Zacks4 months ago

    Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?

    Smart Beta ETF report for XHE